Vaccine Shield Protecting Children from HIV

Unlocking Immunity: How Early HIV Treatment Impacts Vaccine Response in Children

Samir D’Costa in Health & Wellness June 2025 • 4 min read.

"A Deep Dive into Diphtheria, Tetanus, Pertussis, and Hepatitis B Vaccine Effectiveness"

Vaccines are a cornerstone of public health, protecting against a range of infectious diseases. For children, especially those exposed to or infected with HIV, ensuring vaccines are effective is critical. A recent study published in Expert Review of Vaccines sheds light on how the timing of antiretroviral therapy (ART) affects the immune memory responses to common childhood vaccines, including diphtheria, tetanus, pertussis, and hepatitis B.

HIV infection can disrupt the body's immune system, potentially reducing the effectiveness of vaccines. This disruption can lead to lower rates of seroconversion (the development of antibodies after vaccination), faster decline of antibody levels, and impaired generation of memory B-lymphocytes, which are essential for long-term immunity. Given these challenges, researchers are exploring ways to optimize vaccine responses in HIV-infected infants, with a particular focus on the timing of ART initiation.

This article delves into the findings of the study, offering insights into the impact of early versus delayed ART initiation on vaccine responses in children exposed to HIV. By understanding these dynamics, healthcare providers and policymakers can make informed decisions to protect this vulnerable population.

The Study: Timing is Everything When It Comes to ART and Vaccine Response

Vaccine Shield Protecting Children from HIV

The study, conducted in South Africa, followed a cohort of HIV-unexposed, HIV-exposed but uninfected, and HIV-infected children. The HIV-infected children were randomized to start ART either early (at 6–10 weeks of age) or later, based on clinical or immunological indicators. All children received the standard DTwP-HibCV (diphtheria-tetanus-whole cell pertussis-Haemophilus influenzae type b conjugate vaccine) and hepatitis B vaccines, followed by a DTwP booster dose at 15–18 months. Researchers then measured antibody levels before and after the booster, as well as at 24 months of age, to assess immune memory and antibody persistence.

The primary goal was to evaluate how early ART initiation affects memory responses and antibody persistence to the DTwP and Hepatitis B vaccines. The researchers looked at several key indicators:

Antibody levels (Geometric Mean Concentrations or GMCs) for pertussis-toxoid, filamentous hemagglutinin (FHA), diphtheria-toxoid, tetanus-toxoid, and hepatitis B.
Proportion of children achieving protective antibody levels (≥0.1 IU/ml for diphtheria and tetanus; ≥10 mIU/ml for hepatitis B).
Fold-increase in antibody levels after the booster dose.

By comparing these measures across the different groups, the study aimed to determine the optimal timing for ART initiation to maximize vaccine effectiveness in HIV-exposed and infected children.

The Takeaway: Early Intervention for Stronger Immunity

This research underscores the critical importance of early ART initiation in HIV-infected infants. By starting ART promptly, these children can achieve better vaccine responses and maintain protective antibody levels, setting them up for healthier lives. These findings have important implications for public health policies and clinical practice, highlighting the need for early HIV diagnosis and treatment to ensure optimal vaccine effectiveness and long-term health outcomes for children exposed to or infected with HIV.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

Why is early antiretroviral therapy (ART) initiation so important for children exposed to or infected with HIV?

Early initiation of antiretroviral therapy (ART) is crucial because HIV can disrupt the immune system, diminishing the effectiveness of vaccines. Starting ART promptly helps mitigate these effects. This enables children to develop better immune responses to vaccines like DTwP (diphtheria-tetanus-whole cell pertussis) and Hepatitis B, and helps them maintain protective antibody levels. The goal is to ensure robust long-term immunity and improved health outcomes, making early ART a key factor in public health strategies for this vulnerable population.

How does HIV infection affect a child's immune response to vaccines?

HIV infection can significantly impair a child's immune response to vaccines. Specifically, it can lead to reduced rates of seroconversion, meaning fewer children develop antibodies after vaccination. Furthermore, antibody levels tend to decline more rapidly, and the generation of memory B-lymphocytes, essential for long-term immunity, is often impaired. These factors collectively diminish the effectiveness of vaccines, highlighting the need for interventions like early antiretroviral therapy to counteract these effects.

What vaccines were specifically studied in relation to early ART initiation?

The study focused on the DTwP-HibCV (diphtheria-tetanus-whole cell pertussis-Haemophilus influenzae type b conjugate vaccine) and hepatitis B vaccines. Researchers measured antibody levels before and after a booster dose of DTwP, assessing immune memory and antibody persistence. Key indicators examined included antibody levels for pertussis-toxoid, filamentous hemagglutinin (FHA), diphtheria-toxoid, tetanus-toxoid, and hepatitis B, as well as the proportion of children achieving protective antibody levels. These vaccines were chosen because they are critical for protecting children from common infectious diseases and represent a broad evaluation of vaccine response.

What were the key findings related to the timing of ART and vaccine effectiveness?

The primary finding underscored the critical importance of initiating antiretroviral therapy (ART) early in HIV-infected infants. The study demonstrated that children who started ART promptly achieved better vaccine responses and maintained protective antibody levels compared to those who started ART later. This was evaluated by measuring antibody levels before and after the DTwP booster, and at 24 months. The research also looked at antibody levels for pertussis-toxoid, filamentous hemagglutinin (FHA), diphtheria-toxoid, tetanus-toxoid, and hepatitis B, as well as the proportion of children achieving protective antibody levels. The results suggest that early ART is key to optimizing vaccine effectiveness and ensuring long-term health outcomes.

What are the implications of these findings for healthcare providers and public health?

The findings emphasize the need for early HIV diagnosis and treatment to ensure optimal vaccine effectiveness and long-term health outcomes for children exposed to or infected with HIV. Healthcare providers should prioritize early antiretroviral therapy (ART) initiation for HIV-infected infants to maximize vaccine responses. Public health policies should focus on strategies for early HIV detection, prompt ART initiation, and monitoring of vaccine responses in this vulnerable population. These actions can help ensure that children receive the full benefit of essential vaccines such as DTwP (diphtheria-tetanus-whole cell pertussis) and Hepatitis B, protecting them from infectious diseases.